Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYNNASDAQ:TGTXNASDAQ:TLXNASDAQ:VRNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$11.70-3.3%$10.37$6.36▼$47.45$1.33B1.191.67 million shs1.97 million shsTGTXTG Therapeutics$33.40+0.1%$38.86$15.16▼$46.48$5.30B2.213.02 million shs1.77 million shsTLXTelix Pharmaceuticals Limited American Depositary Shares$16.40-1.9%$17.06$13.61▼$30.36$5.54BN/A27,312 shs9,144 shsVRNAVerona Pharma$67.24-0.5%$63.29$11.39▼$74.18$5.45B0.21.29 million shs1.31 million shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics-3.66%+20.16%+71.88%-13.07%-54.55%TGTXTG Therapeutics-4.63%-4.27%-9.10%+7.99%+92.67%TLXTelix Pharmaceuticals Limited American Depositary Shares+2.83%-8.59%+0.36%-5.06%+1,670,999,900.00%VRNAVerona Pharma+0.06%-3.57%+17.09%+7.77%+386.82%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDYNDyne Therapeutics3.5443 of 5 stars4.52.00.00.03.83.30.0TGTXTG Therapeutics3.883 of 5 stars2.43.00.03.52.61.71.9TLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/AN/AN/AN/AN/AN/AVRNAVerona Pharma3.1203 of 5 stars3.63.00.00.03.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYNDyne Therapeutics 3.07Buy$46.85300.39% UpsideTGTXTG Therapeutics 2.80Moderate Buy$40.8022.16% UpsideTLXTelix Pharmaceuticals Limited American Depositary Shares 3.00Buy$22.0034.15% UpsideVRNAVerona Pharma 3.11Buy$81.5021.21% UpsideCurrent Analyst Ratings BreakdownLatest DYN, TGTX, TLX, and VRNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $38.005/9/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.004/30/2025VRNAVerona PharmaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$93.00 ➝ $107.004/30/2025VRNAVerona PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$75.00 ➝ $85.004/28/2025VRNAVerona PharmaCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy4/28/2025VRNAVerona PharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$100.004/21/2025VRNAVerona PharmaCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$80.003/21/2025DYNDyne TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $17.003/17/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.003/17/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.003/12/2025DYNDyne TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$50.00(Data available from 5/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/ATGTXTG Therapeutics$386.39M13.72$0.09 per share353.90$1.06 per share31.51TLXTelix Pharmaceuticals Limited American Depositary Shares$783.21M7.08N/AN/AN/A∞VRNAVerona Pharma$118.54M45.99N/AN/A$3.10 per share21.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYNDyne Therapeutics-$235.94M-$3.59N/AN/AN/AN/A-57.46%-51.62%N/ATGTXTG Therapeutics$12.67M$0.24N/A33.40N/A-5.42%-8.32%-3.40%N/ATLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/A0.0034.17N/AN/AN/AN/AN/AVRNAVerona Pharma-$54.37M-$2.00N/A2,241.33N/AN/A-79.54%-43.49%N/ALatest DYN, TGTX, TLX, and VRNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/7/2025Q1 2025TGTXTG Therapeutics$0.19$0.03-$0.16$0.03$117.07 million$120.86 million4/29/2025Q1 2025VRNAVerona Pharma-$0.22$0.27+$0.49-$0.16$41.47 million$98.65 million3/4/2025Q4 2024DYNDyne Therapeutics-$0.92-$0.88+$0.04-$0.88N/AN/A3/3/2025Q4 2024TGTXTG Therapeutics$0.08$0.15+$0.07$0.15$100.67 million$108.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDYNDyne TherapeuticsN/AN/AN/AN/AN/ATGTXTG TherapeuticsN/AN/AN/AN/AN/ATLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/AN/AN/AVRNAVerona PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYNDyne TherapeuticsN/A17.0217.02TGTXTG Therapeutics1.274.593.91TLXTelix Pharmaceuticals Limited American Depositary SharesN/AN/AN/AVRNAVerona Pharma0.9313.0312.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYNDyne Therapeutics96.68%TGTXTG Therapeutics58.58%TLXTelix Pharmaceuticals Limited American Depositary SharesN/AVRNAVerona Pharma85.88%Insider OwnershipCompanyInsider OwnershipDYNDyne Therapeutics14.14%TGTXTG Therapeutics10.50%TLXTelix Pharmaceuticals Limited American Depositary SharesN/AVRNAVerona Pharma4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYNDyne Therapeutics100113.63 million80.63 millionOptionableTGTXTG Therapeutics290158.78 million139.32 millionOptionableTLXTelix Pharmaceuticals Limited American Depositary SharesN/A337.88 millionN/AN/AVRNAVerona Pharma3081.08 million76.10 millionOptionableDYN, TGTX, TLX, and VRNA HeadlinesRecent News About These CompaniesWhy Verona Pharma plc (VRNA) is Among the Best Performing Healthcare Stocks to Buy NowMay 13 at 12:09 PM | insidermonkey.comFred Alger Management LLC Takes $1.34 Million Position in Verona Pharma plc (NASDAQ:VRNA)May 13 at 6:03 AM | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Shares Acquired by Barclays PLCMay 13 at 3:20 AM | marketbeat.comFindell Capital Management LLC Makes New $8.36 Million Investment in Verona Pharma plc (NASDAQ:VRNA)May 11 at 7:37 AM | marketbeat.comThe Manufacturers Life Insurance Company Has $5.89 Million Stock Position in Verona Pharma plc (NASDAQ:VRNA)May 10, 2025 | marketbeat.comDeep Track Capital LP Sells 2,330,025 Shares of Verona Pharma plc (NASDAQ:VRNA)May 9, 2025 | marketbeat.comDuquesne Family Office LLC Purchases 201,535 Shares of Verona Pharma plc (NASDAQ:VRNA)May 9, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Insider Sells $1,014,158.88 in StockMay 9, 2025 | insidertrades.comWhat Makes Verona Pharma plc (VRNA) a Good Investment?May 8, 2025 | insidermonkey.comWhat Makes Verona Pharma plc (VRNA) a Good Investment?May 8, 2025 | msn.comCaxton Associates LP Acquires New Position in Verona Pharma plc (NASDAQ:VRNA)May 8, 2025 | marketbeat.comBeverly Hills Private Wealth LLC Purchases Shares of 5,566 Verona Pharma plc (NASDAQ:VRNA)May 8, 2025 | marketbeat.comAxa S.A. Sells 74,142 Shares of Verona Pharma plc (NASDAQ:VRNA)May 8, 2025 | marketbeat.comVerona Pharma Presents Positive Phase 3 Analyses of Ohtuvayre® for COPD at ATS 2025May 7, 2025 | nasdaq.comVerona Pharma Presents Positive Phase 3 Analyses of Ohtuvayre® for COPD at ATS 2025May 7, 2025 | nasdaq.comBellevue Group AG Trims Holdings in Verona Pharma plc (NASDAQ:VRNA)May 6, 2025 | marketbeat.comVerona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025May 6, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Increases Stock Holdings in Verona Pharma plc (NASDAQ:VRNA)May 6, 2025 | marketbeat.comVerona Pharma plc (NASDAQ:VRNA) Sees Large Decline in Short InterestMay 5, 2025 | marketbeat.comVoya Investment Management LLC Has $2.77 Million Position in Verona Pharma plc (NASDAQ:VRNA)May 5, 2025 | marketbeat.comHC Wainwright Boosts Earnings Estimates for Verona PharmaMay 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumMedtronic: A Dividend Aristocrat With Stability and InnovationBy Jeffrey Neal Johnson | April 22, 2025View Medtronic: A Dividend Aristocrat With Stability and InnovationWingstop Stock Jumps on Q1 Beat, Expansion OutlookBy Jeffrey Neal Johnson | May 4, 2025View Wingstop Stock Jumps on Q1 Beat, Expansion OutlookStrategists Say Hold: Stocks May Beat the 'Sell in May' TrendBy Jeffrey Neal Johnson | May 9, 2025View Strategists Say Hold: Stocks May Beat the 'Sell in May' TrendDYN, TGTX, TLX, and VRNA Company DescriptionsDyne Therapeutics NASDAQ:DYN$11.70 -0.40 (-3.31%) As of 04:00 PM EasternDyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.TG Therapeutics NASDAQ:TGTX$33.40 +0.03 (+0.09%) As of 04:00 PM EasternTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.Telix Pharmaceuticals Limited American Depositary Shares NASDAQ:TLX$16.40 -0.31 (-1.86%) As of 04:00 PM EasternTelix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.Verona Pharma NASDAQ:VRNA$67.24 -0.33 (-0.49%) As of 04:00 PM EasternVerona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SMCI Stock Rally: 45% Gain in 2 Days Could Be Just the Start AMD’s AI-Powered Stock Price Rally Just Shifted Gears Oklo Reaches Critical Mass, Atomic Upside Still Available Is Verizon a Buy? Q1 Results and Solid Dividend Make Bullish Case Carnival's Comeback: Is the Stock Set for a Profitable Journey? 5 Hot Small-Cap Insiders Bought at the Peak of Tariff Fears U.S. Regulators Target CrowdStrike: Is It a Signal or Noise? Insulet Surges on Q1 Beat, Emerges as a Top S&P 500 Performer Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
